DGAP-Adhoc Heidelberg Pharma AG: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

Nachrichtenquelle: EQS Group AG
04.02.2021, 10:57  |  144   |   |   

DGAP-Ad-hoc: Heidelberg Pharma AG / Key word(s): Study
Heidelberg Pharma AG: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

04-Feb-2021 / 10:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement - Inside information pursuant to Article 17 MAR

FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101

Ladenburg, Germany, 4 February 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that the US Food and Drug Administration (FDA) has informed the company it is safe to proceed with the Phase I/IIa study with the BCMA Antibody Targeted Amanitin Conjugate, HDP-101 that was submitted under its US IND. The study will evaluate HDP-101 for the treatment of multiple myeloma, a blood cancer with high unmet medical need.

The first part of the trial is a Phase I dose escalation study to determine the maximum tolerated dose of HDP-101. The findings from Phase I will be used to establish the dose for the Phase IIa portion of the trial, the primary objective of which is to assess the preliminary anti-tumor activity of HDP-101.

The two parts of the open-label, multicenter Phase I/IIa study will enroll up to 36 and 30 patients, respectively. Patients in the Phase IIa part will be stratified based on their 17p deletion status. Preclinical data show that Amanitin has the potential to be especially effective against tumors that have changed due to so-called 17p deletion mutations to bypass a special mechanism of cell protection. Patients with such a deletion usually show a poorer response to standard therapies and have a significantly worse prognosis. The Phase IIa part of the trial is intended to evaluate not only the efficacy of HDP-101 in multiple myeloma patients, but also the clinical relevance of the 17p deletion.

Seite 1 von 3


Diesen Artikel teilen



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-Adhoc Heidelberg Pharma AG: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 DGAP-Ad-hoc: Heidelberg Pharma AG / Key word(s): Study Heidelberg Pharma AG: FDA Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate HDP-101 04-Feb-2021 / 10:57 CET/CEST Disclosure of an inside information acc. to …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

COMMUNITY

ZeitTitel
27.02.21
17.06.20